2 news items
Chromocell CEO Issues Letter To Stockholders
CHRO
9 Apr 24
demonstrated no liver or renal toxicity, no central nervous system changes and no cardiovascular findings. With no central nervous system changes, patients
Chromocell Issues Letter to Stockholders from Chief Executive Officer
CHRO
9 Apr 24
. The Phase I results demonstrated no liver or renal toxicity, no central nervous system changes and no cardiovascular findings. With no central nervous system
- Prev
- 1
- Next